RISK WARNING: Your capital is at risk. The risks include: the lack of liquidity in this market in terms of being able to realise investments and the loss of the value of investment. When you invest any loss in value will not be covered by the Financial Services Compensation Scheme. Please read FULL risk warning.
Sutrue has created and patented the world’s first intrinsically safe automated suturing device.
A pledge is not a commitment. You will be asked to confirm in the next section.
This company has not shared it's twitter feed.
Sutrue devices produce a perfect suture at the touch of a button, with improved speed, accuracy and clinical quality. The enclosed needle, held in a disposable cartridge, answers the unresolved safety issue of needlestick injury (accidental penetration of the skin with a potentially contaminated needle) when suturing in both the medical and veterinary surgical settings, protecting surgeons and ancillary staff during and after surgery.
The Sutrue devices enable healthcare employers to meet their legal obligations. Professional bodies such as the American Nurses Association (ANA) are pressing industry for solutions - “Manufacturers partner with surgeons and surgeon groups to develop suture and scalpel designs that both reduce risk and are comfortable and intuitive for surgeons to use….”
Deal Type: Equity
Geographical Focus: UK
About: Sutrue has created and patented the world’s first intrinsically safe automated suturing devices for both standard and endoscopic wound closure that use industry-standard needles.
Type: Company raising finance
Contact Name: Nia Dokova
Date established: March 2012
Date Joined Envestry: November 2018